IS5233A - Diagnosis of reward deficiency syndrome and its preparations - Google Patents

Diagnosis of reward deficiency syndrome and its preparations

Info

Publication number
IS5233A
IS5233A IS5233A IS5233A IS5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A IS 5233 A IS5233 A IS 5233A
Authority
IS
Iceland
Prior art keywords
preparations
diagnosis
deficiency syndrome
reward deficiency
reward
Prior art date
Application number
IS5233A
Other languages
Icelandic (is)
Inventor
Blum Kenneth
E. Comings David
L. Ivy John
Original Assignee
Kenneth Blum, Inc.
Board Of Regents, The University Of Texas System
City Of Hope National Mecical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Blum, Inc., Board Of Regents, The University Of Texas System, City Of Hope National Mecical Center filed Critical Kenneth Blum, Inc.
Publication of IS5233A publication Critical patent/IS5233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
IS5233A 1997-04-29 1999-10-28 Diagnosis of reward deficiency syndrome and its preparations IS5233A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4439497P 1997-04-29 1997-04-29
PCT/US1998/008684 WO1998048785A2 (en) 1997-04-29 1998-04-29 Allelic polygene diagnosis of reward deficiency syndrome and treatment

Publications (1)

Publication Number Publication Date
IS5233A true IS5233A (en) 1999-10-28

Family

ID=21932148

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5233A IS5233A (en) 1997-04-29 1999-10-28 Diagnosis of reward deficiency syndrome and its preparations

Country Status (10)

Country Link
EP (1) EP0979092A2 (en)
JP (1) JP2002511850A (en)
KR (1) KR20010020422A (en)
CN (1) CN1261801A (en)
AU (1) AU7267798A (en)
CA (1) CA2288990A1 (en)
IL (1) IL132634A0 (en)
IS (1) IS5233A (en)
NO (1) NO995257L (en)
WO (1) WO1998048785A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
GB9927806D0 (en) 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
ATE329620T1 (en) * 2000-12-01 2006-07-15 Be Able Llc BEHAVIOR CHEMOTHERAPY
ITRM20010218A1 (en) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION OR TREATMENT OF LEARNING DISORDERS IN CHILDREN AFFECTED BY ATTENTION DEFICIT AND HYPERACTIVE
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
CN103497993A (en) * 2005-02-07 2014-01-08 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
US8572472B2 (en) 2006-09-28 2013-10-29 Mitsubishi Electric Corporation Fault detection apparatus, fault detection method, and fault detection program
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
JP2011528321A (en) * 2008-06-21 2011-11-17 ケンバー，エルエルシー Nutrigenomics method and composition
WO2010005303A2 (en) * 2008-07-07 2010-01-14 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum New indicators of human longevity and biological ageing rate
AU2011234422B2 (en) 2010-04-01 2015-11-05 Ecole Polytechnique Federale De Lausanne (Epfl) Device for interacting with neurological tissue and methods of making and using the same
WO2011133949A2 (en) * 2010-04-22 2011-10-27 Kenber, Llc Genetic risk analysis in reward deficiency syndrome
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
JP2015067581A (en) * 2013-09-30 2015-04-13 国立大学法人京都大学 Probe for multiple resonance
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN103990106A (en) * 2014-06-11 2014-08-20 河北医科大学 Application of cholecystokinin octapeptide in medicine preparation
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
CN104846015B (en) * 2015-05-27 2018-03-27 深圳先进技术研究院 The composition of GABA serotonergic neurons in special heat nucleus accumbens septi and its application in schizophrenia difference behavior is improved
CN109069824B (en) * 2016-02-02 2022-09-16 阿莱瓦神经治疗股份有限公司 Treatment of autoimmune diseases using deep brain stimulation
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
DE102018114364B4 (en) 2018-06-15 2026-04-23 Susanne Koch Devices for providing a parameter indicating an increased likelihood of postoperative delirium.
CN109316196B (en) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） Amphetamine stimulant craving assessment method based on virtual reality and electroencephalogram monitoring
CN110507294B (en) * 2019-08-07 2022-02-08 北京安龙脉德医学科技有限公司 First-aid system based on internet information transmission
CN110991044B (en) * 2019-12-03 2023-02-24 北京机电工程研究所 Agent-Based Modeling Method for Aircraft System Mission Reliability Evaluation
CN112862751B (en) * 2020-12-30 2022-05-31 电子科技大学 Automatic diagnosis device for autism
CN113332299A (en) * 2021-05-27 2021-09-03 广东湛江海洋医药研究院 Application of salidroside in relieving glucocorticoid-induced osteoporosis
KR102434668B1 (en) * 2022-03-02 2022-08-22 주식회사 국개대표 Feed for pets that can improve separation anxiety symptoms and manufacturing thereof
CN115830001B (en) * 2022-12-22 2023-09-08 抖音视界有限公司 Intestinal tract image processing method and device, storage medium and electronic equipment
CN116310717B (en) * 2023-02-14 2025-06-20 长沙理工大学 Target student network model training method and low-resolution image recognition method
CN116820166B (en) * 2023-06-08 2024-07-19 武汉汉联智控科技有限公司 High-low temperature control flow control system and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity

Also Published As

Publication number Publication date
CN1261801A (en) 2000-08-02
JP2002511850A (en) 2002-04-16
EP0979092A2 (en) 2000-02-16
WO1998048785A2 (en) 1998-11-05
KR20010020422A (en) 2001-03-15
WO1998048785A9 (en) 1999-05-20
NO995257D0 (en) 1999-10-28
CA2288990A1 (en) 1998-11-05
NO995257L (en) 1999-12-27
IL132634A0 (en) 2001-03-19
AU7267798A (en) 1998-11-24
WO1998048785A3 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
NO995257D0 (en) Procedure and materials for diagnosis and treatment of Reward Deficiency Syndrome
NO994778L (en) Methods and Preparations for the Treatment of Inflammatory Bowel Syndrome
NO993868D0 (en) 3-piperidyl-4-oxoquinazoline derivatives and medical preparations containing them
NO20000943L (en) 5-alkyl-2-arylaminophenylacetic acids and derivatives
NO20000700D0 (en) Interleukin-18 proteins and their preparation and use
DK1112174T3 (en) Isosorbide-containing polyesters and processes for their preparation
DK0745396T3 (en) Blood pump and its use
DK0865778T3 (en) Hygienic and medical products
NO993339D0 (en) Fluid mixer and associated process
NO20001488L (en) Pre-filled ampoules and their preparation
NO983364L (en) Consensus Proteins
NO983576D0 (en) Well treatment fluids and methods
NO20001552D0 (en) Catalyst and processes where used
DK0991666T3 (en) Alpha-1-antitrypsin preparation and process for its preparation
NO993731L (en) Pyrrolopyrazolopyrimidine compound and medicine comprising this
PT878467E (en) 6-AMINOTETRAHYDROISOQUINOLINACARBOXYLIC ACID AND SUBSTITUTED 7-AMINOTETHYDROISOQUINOLINACARBOXYLS
DK1047445T3 (en) MODIFIED ENZYMES AND ITS APPLICATION FOR PEPTIDE SYNTHESIS
NO982181D0 (en) Type IX collagen and chimeras
NO971505D0 (en) Trophine and trophine helper proteins
NO20012738D0 (en) Therapeutic products and their use
IS2065B (en) Dosing and cooking equipment for products
EP1018551A4 (en) MEGSINE PROTEIN
DE69837507D1 (en) Human hedgehog protein
EP1012262A4 (en) HUMAN FREZZELED-LIKE PROTEIN
EP0679051A3 (en) Contacting of actuating and display means.